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NEWER ANTIMYCOBACTERIAL DRUGS AND THEIR ROLE IN THE
TREATMENT OF TUBERCULOSIS PATIENTS
C.N. Paramasivan
Chemotherapy of pulmonary tuberculosis :
current concepts and need for newer drugs
The main lesion in pulmonary tuberculosis, the
pulmonary cavity, contains a large number of
mycobacteria (about 108 colony forming units). Of
these, a large bacillary population is located in the
thin liquid caseous layer that covers the inner part
of the cavitary wall. Here, the bacilli are
extracellular which multiply actively because of
the availability of oxygen and nutritive
substances. There are at least 2 other bacillary
populations, one inside macrophages and another
inside solid caseous foci; both these populations
are limited in size because environmental
conditions are unfavourable for their growth.1
Among the organisms in these 3 populations,
which are normally drug sensitive, drug
resistant mutants develop at a mean frequency of
about 10-6.
In the early sixties, chemotherapy for
tuberculosis relied on the administration of 18 to
24 months of 3 drugs : Isoniazid (H), Para-amino
salicylic acid (PAS) and Streptomycin (S), the last
being given during the initial few months of.
treatment. The drugs were given together to
Prevent the emergence of resistance and
prolonged treatment was given until the microbial
population was eliminated in order to prevent
relapse. Despite such prolonged treatment the
relapse rate after discontinuation of treatment was
about 10%.1
The introduction of Rifampicin (R), in the
seventies, brought a marked change in the
chemotherapy of tuberculosis.2 Rifampicin was
effective not only against actively multiplying
organisms but also against the dormant or
persisting organisms, responsible for relapse after
treatment was stopped. Around this time, the
bactericidal activity of Pyrazinamide (Z), a drug
highly active against organisms located in an acid
environmental, especially inside macrophages, was
also rediscovered These developments formed the
basis of controlled clinical trials which established
the efficacy of 6-month regimens. The high
ucc ss rate of antituberculosis regimens of only 6
months duration in the treatment of extensive
sputum positive, pulmonary tuberculosis was
clearly demonstrated in a large scale study in East
Africa.3 This led to the recommendation by
numerous health authorities of the 6-month short
course chemotherapy (SCC) for tuberculosis that
is presently used in many countries, including
Indi
T  major drugs,whose potency and
cceptability have resulted in their widespread use
in the current chemotherapy of pulmonary
tuberculosis are H, R Z, S, Ethambutol (Emb) and
Thioacetazone (TB1).4 The usefulness of a drug in
the treatment of tuberculosis depends mainly on
its sterilising activity; ability in combination with
H to prevent-emergence of resistance and early
bactericidal activity. The time taken for organs to
be s erilised, in experimental animal tuberculosis
and the relapse rate after SCC in man are
measures of a drug’s action against semidormant
tubercle bacilli and its sterilising activity. The
abili y of a drug to prevent the emergence of
resistance is assessed during treatment with the
drug concerned in combination with H, and is
graded according to the proportion of patients who
fail, with the emergence of H resistance; this
proportion is about 0.5% for Rifampicin (high
activity) and 13-15% for Thioacetazone (low
activity).5 The fall in the count of viable tubercle
bacilli during the first few days of treatment, when
the actively growing bacilli are killed, is termed
the early bactericidal activity (EBA) and can be
measured in vitro, or in man.
Tubercle bacilli in a special population which
show spurts of metabolism are particularly
susceptible to Rifampicin and the ones in a special
populationsurrounded by an acid environment are
suceptible to Pyrazinamide. H and R are highly
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effective in preventing the emergence of
resistance, H has high EBA, R and Z have high
sterilising action, and H, R, Z Emb and S are
highly suitable for intermittent use.4
Despite the introduction of effective, nontoxic
antituberculosis drugs and therapeutic regimens,
pulmonary tuberculosis still affects millions of
people in the developing world.6 The results of a
recent evaluation done by the Tuberculosis Re-
search Centre (TRC), Madras7 show that the real-
ity of the tuberculosis problem remains grim even
after the implementation of SCC. Of the 3357
smear-positive pulmonary tuberculosis patients
initiated on antituberculosis treatment in North
Arcot district between April 1986 and March
1988, 2306 had been prescribed a SCC regimen
and 1051 had accepted a standard regimen. Only
43% receiving the SCC and 35% receiving the
standard regimen had completed 80% or more of
their treatment. The overall mortality was 28%.
Of the remaining, 31% had active disease and
were excreting bacilli, including 65% whose cul-
tures were resistant to H and 12% to R, combined
resistance to R & H was seen in 6% and to S & H
in 19%. H resistance was significantly higher in
those who had been prescribed standard regimens
and R resistance was seen even in those who had
not received the drug.
Even with the standard regimens, it was
possible to achieve 98% cure rate and reduce
mortality rate to as low as 1% in clinical trials.8
However, when these regimens were applied
under field conditions, less favourable results
were obtained, the reason being the difficulty in
delivering the presently available complex
regimens to patients in tuberculosis control
programmes, particularly in developing countries
like India.9 Partly as a consequence of poor
adherence, a sizeable proportion of patients
harbour tubercle bacilli resistant to one or more
established drugs, which further complicates
treatment.10-12
Thus, new chemotherapeutic drugs are needed
to improve adherence and to treat disease due to
drug resistant tubercle bacilli and nontuberculous
mycobacteria (NTM). At present, and in the near
future, the control of tuberculosis will depend on
better case-finding, case-holding and treatment.
For this, the availability of well tolerated and
rapidly curative drugs that can be delivered by
peripheral centres is essential.4 The new drugs
must be developed with the aim of increasing
t e sterilising activity of regimens because
they might allow further shortening of the
period of treatment to less than the current 6
months and, thus, improve adherence and
acceptability.
The duration of treatment, the number of drugs
used and the frequency of administration of each
drug determine the complexity of therapy.
Complexity and toxicity often lead to poor
adh rence. Several strategies have been developed
to simplify treatment, to reduce medication errors
and o discourage intentional avoidance of the
ingestion of one or more drugs. New formulations
containing 2 or more drugs, such as combination
tabl ts containing both R and H, and more
rece tly R, H and Z, with bioavailability of the
components equivalent to that when single drugs
are administered have been developed. Implants
of biodegradable polymeric systems such as
polyactic polyglycolic and poly (lactic/glycolic)
acid copolymers containing antituberculosis drug,
for sustained release of the drug, could help in
solving the non-adherence problem. However,
with the potency of the present antituberculosis
drugs, the implants will have to be very large and
the cost of surgical implant and removal after drug
cessation increases the cost of chemotherapy.13
The financial resources and time needed for
developing a new antituberculosis drug and
assessing its efficacy in vitro and in clinical trials,
the decline of tuberculosis in developed countries,
the inability of developing countries to purchase
expensive drugs and the ready availability of
effective antituberculosis drugs are some of the
reasons why new agents for the treatment of
tuberculosis have not appeared.14 However. the
cu rent increase in the incidence of tuberculosis
associated with HIV infection, and the occurrence
of multiple-resistant tubercle bacilli have led to a
pressing need for the rapid development of new
antituberculosis drugs. The second urgent need for
n w rugs arises because of anticipated future
increase in the incidence of R resistant strains. In
the treatment of tuberculosis, SCC regimens are
eff ctive in patients with strains resistant to H or
S, but the results in patients with initial R
resistance are poor.4
Methods of assessing new drugs
Apart from pharmaceutical firms which
develop them, new drugs have to be assessed
independently through in vitro studies, animal
experiments and clinical investigations to allow
unbiased comparisons between drugs and to make
such assessments as free as possible from
commercial interests. In vitro studies include
determination of the minimal inhibitory
concentration (MIC) and the bactericidal activity
against appropriate mycobacterial species. Animal
experiments include estimation of blood levels,
chemotherapeutic studies, preferably in mouse
and occasionally also in guinea pig, and
measurement of sterilising activity. In clinical
investigations of antituberculosis drugs, a series of
single increasing doses of the new drug is given to
patients or healthy volunteers, while information
 on pharmacokinetics and side effects is obtained.
The effective dose size is estimated by measuring
EBA of the new drug at different dose sizes in
 comparison with a standard drug such as
  Rifampicin. These studies have to be followed by
pilot and full scale clinical trials.4
ROLE OF NEWER ANTIMYCOBACTERIAL DRUGS 9
M. avium-intracellulare and the emerging
problem of disseminated M. avium intracellulare
infection in patients with AIDS led to the use of
the drug in USA on ‘compassionate’ grounds,
bef re clinical trials, but with disappointing
results.15-16
Rifabutin was alsoactive against
approximately one third of the Rifampicin
resistant strains of M. tuberculosis tested.16 All
M. tuberculosis strains susceptible to Rifampicin
were susceptible to Ansamycin, and the MICs
were similar. The strains that were highly resistant
to Rifampicin were resistant to Ansamycin.
However, it showed activity against some
Rifampicin resistant M. tuberculosis strains.
Typical MIC for M. tuberculosis strains was
obs rved to be 0.006 mg/l for Rifampicin
sensitive strains and 6-16 mg/l for Rifampicin
resistant strains. The MICs for resistant strains are
much higher than clinically achievable
concentration in blood (C max-0.5 mg/l blood
after 300 mg given orally; C max 3 mg/l in lung
tissues).”
Promising newer antimycobacterial drugs
Based on all or some of the above mentioned
methods of assessment, a few classes of drugs
show promise in the treatment of tuberculosis.
These include the Rifamycin derviatives,
fluoroquinolones, combination of beta lactam
agents and beta lactamase inhibitors, and others.
Rifamycin derivatives
The dose required when Rifampicin is given
Once weekly may lead to a high incidence of
serious adverse reactions. This can be avoided by
using a Rifamycin with a long half-life which
gives sustained blood levels between doses. Many
novel Rifamycin molecules with a long
elimination half-life have been designed with this
aim.2 Such long lasting Rifamycins (LLRs)
include Rifabutin (LM 427, Ansamycin-
Farmitalia), Rifapentine (DL 473-Merrel Dow),
CGP 29861, CGP 7040 and CGP 27557 (Ciba-
Geigy), FCE 22250 (Farmitalia). and R-76-l
(Rifadine) developed in China.
Rifabutin (LM 427, Ansamycin)
Rifabutin is a semisynthetic spiropiperidyl
derivative. The discovery of its activity against
Dickinson and Mitchison18 observed that 31%
of 35 Rifampicin resistant strains tested had MICs
of 0.6 mg/l or less for Rifabutin and could be
classified as relatively sensitive. The MICs of
Rifabutin were much lower among sensitive M.
tuberculosis strains. As an explanation for the low
MICs of Rifabutin against Rifampicin resistant
strains, it has been claimed that the mode of action
of Rifabutin is different from that of Rifampicin.
Alternatively, this would also suggest that the
activity of Rifabutin and other Rifamycins against
resistant strains might be proportional to their
activity against sensitive strains. These findings
raise the possibility that Rifabutin might be of use
in the treatment of some patients with Rifampicin
resistant strains.
In a study done at TRC, a total of 103 M.
tuberculosis trains were tested against
Rifampicin and Rifabutin.19 I  42 out of the 52
Rifampicin susceptible strains Rifabutin showed
as least 4-fold higher effectiveness than
Rifampicin. The geometric mean MIC of the 52
strains was 1.3 mg/l with Rifabutin compared to
13.3 mg/l with Rifampicin, showing on an average
10-fold higher effectiveness. Of 51 strains
resistant to Rifampicin, 11(22%) were susceptible
to Rifabutin.
I  animal models, Rifabutin is quite active
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against M. tuberculosis and its relatively high
tissue levels and long half-life suggest that the
drug might be effective if given intermittently in
tuberculosis. It is about 6 times more active than
Rifampicin in experimental infection of mice with
M. tuberculosis orM. avium. The considerable
activity in murine disease may reflect high
intracellular concentrations inmouse
macrophages while caseating lesions in cavitary
walls containing numerous acid fast bacilli,
characteristic of human pulmonary tuberculosis
might contain lower concentrations corresponding
to those in plasma. Thus. it is uncertain whether
Rifabutin concentrations in these human sites are
sufficiently high for effective antimicrobial
activity.20
The fall in viable counts of M. tuberculosis in
sputum collections during the first 2 days of
treatment (EBA) suggested that Rifabutin was
inactive or less active than Rifampicin in
pulmonary cavities.20 This may be due to the low
plasma concentrations which are not fully
compensated for by the slightly greater antituber-
culosis activity of Rifabutin in vitro.
Recently, a controlled study of Rifabutin in the
retreatment of patientswith pulmonary 
tuberculosis resistant to SHR has been reported
by the Hong Kong Chest Service/BMRC.21
Bacteriological results in the 22 patients studied
showed no evidence of sustained benefit in any
patient with Rifampicin or Rifabutin. The results
suggested that Rifabutin does not have a useful
role in the retreatment of patients with multi-drug
resistant pulmonary tuberculosis, which includes
Rifampicin resistance except possibly in a small
proportion of patients who have Rifabutin
susceptible strains.
O’Brien and associates17 have reported their
findings in patients with pulmonary M. vium
complex (MAC) disease and drug resistant
tuberculosis receiving Rifabutin. Conversion rates
were 9% for pulmonary MAC and 35% for drug
resistant tuberculosis. In another study, these
authors have concluded that some patients with
Rifampicin resistant tuberculosis may benefit
from the addition of Rifabutin to the treatment
regimen.22 However, when resistance to all first
line drugs is present, the outcome remains poor.
To obtain an irrefutable answer regarding its
efficacy, Rifabutin should be evaluated in
controlled tests  for the treatment of both newly
diagnosed pulmonary tuberculosis and MAC
pulmonary disease. The drug’s long half-life
suggests that it may be especially valuable for
in ermittent administration. Whether or not this
drug is more effective than Rifampicin can be
answered only by randomized clinical trials.
However, before such trials are initiated, it is
important to determine the optimal dose, lest
fa lu e to show effect be attributed to a sub-
therapeutic dose. It is imperative that controlled
studies of various drug regimens that contain
higher doses of Rifabutin be undertaken for the
tr atment of patients with disseminated MAC
di ease and AIDS.
Rifapentine (DL 473)
Rifapentine, a cyclopentyl Rifamycin has been
shown to have antimycobacterial properties. The
in vitro activity of Rifapentine is 2-4 times that of
Rifampicin against a variety of clinical
mycobacterial isolates; the range of MICs is
0.025-0.1 mg/l as compared with 0.05-0.8 mg/l for
Rifampicin. Rifapentine is bactericidal against
actively growing bacilli, with a rate of killing
similar to that documented for Rifampicin.
In a TRC study, of 103 strains of M.
tuberculosis tested, 51 strains resistant to
Rifampicin (MIC>128) were also resistant to
Rif pentine, indicating complete cross-
resi tance.19 The remaining 52 strains were
sensitive to both; in these strains Rifapentine has a
2 to 16 fold higher activity than Rifampicin.
In experimental tuberculosis in mouse,
Rifapentine has a 50% effective dose (ED 50), 10
times lower than that of Rifampicin. Rifapentine
administered to experimentally infected mice
once a week is as effective as Rifampicin
administered daily, in the initial as well as the
co tinuation phase, and retains considerable
efficacy when given once every 3 weeks. In most
rat tissues, Rifapentine concentrations are about
40 times greater than that observed for
Rifampicin.2 All animal toxicity studies including
long erm assessment have been completed.
Rifapentine has been used in 2 clinical studies,
in man, one in Britain and the other in Finland, far
the treatment of chlamydial urethritis, where it has
been given at 600 mg per day in up to 6
consecutive doses without evidence of toxicity. It
is taken up into the cytosol fraction of neutrophils
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and macrophages and retains intracellular activity.
It binds weakly to serum albumin. After
administration of a single oral dose of 600 mg to
healthy volunteers, peak serum concentrations of
20 mg/l were observed with Rifapentine. The half-
life of Rifapentine after 1st and 3rd once weekly
administration was found to be the same. It has
not yet been used in the treatment of human
tuberculosis. It is potentially of great value in the
chemotherapy of tuberculosis for use in
supervised widely intermittent regimens.4
Fluoroquinolones
Flouroquinolones such as Ofloxacin,
Ciprofloxacin, Norfloxacin, Pefloxacin, Enoxacin,
Lomefloxacin and Sparfloxacin are synthetic
compounds active against a wide variety of
microorganisms. Their activity is exerted through
inhibition of gyrase, an enzyme involved in DNA
replication. As expected, there is no cross
resistance between these agents and other
antituberculosis drugs.2
Ofloxacin (DL 8280)
In 1983, Tsukamura23 showed that Ofloxacin
was active in vitro against M.tuberculosis a  well
as against the potentially pathogenic NTM, M.
kansasii. M. xenopi. M. fortuitum and M.
marinum. While most M. intracellulare s rotypes
of the M. avium complex were inhibited by
Ofloxacin, ‘avium’ serotypes were generally
resistant as were most strains of M. chelonei. In
1985, Tsukamura24 reported that the drug might be
beneficial in the treatment of drug resistant
tuberculosis because no cross resistance between
Ofloxacin and other antituberculosis drugs was
seen in vitro. Spontaneous resistance to Ofloxacin
appeared to occur in about 1 in 106 organisms, a
proportion similar to that for other drugs. It
showed considerable bactericidalactivity at
concentrations a little higher than the MIC. The
combined effect with other antituberculosis agents
seemed to be additive. The development of
resistance to DL 8280 was of an obligatory 2 step
pattern. There are 2 phenotypes. The resistance
levels of these phenotypes are 5 mg/l and 100 mg/
l respectively. There was no resistance beyond
100 mg/l.
Davies et al25 reported in 1987 on the
comparative in vitro efficacy of Ofloxacin,
Ciprofloxacin, Pefloxacin, Enoxacin and
Norfloxacin, on 50 M. tuberculosis strains. The
auth rs concluded that since Ofloxacin and
Ciprofloxacin were shown to have the highest in
vitro activity against mycobacteria, these 2 drugs
could be used in the treatment of M. tuberculosis
resistant to standard drugs. However, in these
studies only M. tuberculosis strains sensitive to
a tituberculosis drugs were tested. A study
concluded recently at TRC shows that there is no
difference in the activity of Ciprofloxacin and
Ofloxacin in drug resistant and susceptible
strains.26 The geometric means MICs were also
similar for both of these drugs for both categories
of strains tested. None of the strains showed an
MIC>4 mg/l in LJ slopes incorporated with the
drugs. Since the mean MIC of Ofloxacin is far
below the peak serum level of 10.7 mg/l attainable
in normal dosage, this drug may have a role in the
treatment of drug resistant tuberculosis.
A few clinical studies have been carried out
with Ofloxacin. Tsukamura27 administered
Ofloxacin in a daily dose of 300 mg in
combination with other drugs for 6-8 months to 19
tuberculosis patients who had failed on
conventional therapy and had organisms resistant
to most of the commonly used antituberculosis
drugs. The patients had been previously treated
for tuberculosis for an average of 16 years; all had
Isoniazid resistant bacilli, and with one exception
had organisms resistant to Rifampicin as well.
Ofloxacin had a demonstrable effect in decreasing
the number of viable M. tuberculosis organisms in
th se patients. Moreover, the fact that 12 patients
acquired in vitro resistance to Ofloxacin and 4 of
these 12 patients had culture conversion indicated
drug activity. Plasma concentrations in excess of
the MICs were generally achieved. No serious
toxic effects were shown among this small group
of patients.
In the uncontrolled study of Ofloxacin in the
retreatmentof patients with pulmonary
tuberculosis resistant to SHR reported by Hong
Kong Chest Service/BMRC,21 of a total of 17
pati nts who had shown no evidence of a
sustained benefit with Rifampicin or Rifabutin
and subsequently retreated with Ofloxacin, 10
sh wed a response,disease becoming and
remaining quiescent in 3. Ofloxacin appeared to
be a better drug to use, in combination with any
companion drugs still available.
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Ciprofloxacin
Marinis and Legakis28 reported that
Ciprofloxacin was active against all strains of M.
tuberculosis sensitive to S, H, R, and Emb and
inhibited almost all strains showing intermediate
sensitivity or resistance to one or more of the
above agents. Nearly all isolates were inhibited at
a concentration of 3.2 mg/l. The same
phenomenon was also observed with atypical
isolates.
An investigation conducted at TRC on 53
isolates of M. tuberculosis sensitive to SHR and
54 isolates resistant to SHR/HR also revealed
more or less similar findings.29 The percentage
distribution of the MICs with the different
categories of strains was similar, there being no
difference between sensitive and resistant strains,
the geometric means being 3.7 and 3.8 mg/l,
respectively.
The expected mean levels of Ciprofloxacin in
plasma after oral doses of 250 and 500 mg are
1.45 and 2.0 mg/l respectively. However, the drug
may achieve levels in pulmonary tissue in excess
of those in serum. In that respect and in the light
of the present results,he achievable
Ciprofloxacin level is expected to inhibit almost
all of the clinically important species of
mycobacteria including those showing resistance
to one or more of the primary antimycobacterial
agents.28
Lomefloxacin
Lomefloxacin is a new difluoroquinolone that
has the additional advantage of having a relatively
long half-life (7-8 h).30 In a study carried out by
Piersimoni et al,31 the MICs of Ciprofloxacin,
Ofloxacin and Lomefloxacin were determined for
90 M. tuberculosis strains isolated from both
AIDS and other patients, including 11 (2.2%)
which showed in vitro resistance to one or more
first line antituberculosis drugs. The MIC range
for Ciprofloxacin was 0.125 to 4.0 mg/l; for
Ofloxacin 0.25 to 4.0; and for Lomefloxacin 0.5
to 4.0 mg/l. On the basis of these data and also
based on studies by Chen et al,32 the authors
proposed the MIC of 1.0 mg/l as susceptible break
point for both Ciprofloxacin and Ofloxacin and 2
mg/l for Lomefloxacin. These MICs are below
the peakconcentrations of the drugs in human
serum, that is, 10.7 mg/l for Ofloxacin, 2.9 mg/l
for Ciprofloxacin and 4.9 mg/l for Lomefloxacin.
These peak concentrations were attained after
single oral doses of 600, 1000 and 400 mg
respectively. The authors felt that although none
of th se quinolones had been approved for use
against M. tuberculosis, combination therapy will
probably be recommended for fluoroquinolones as
for other antimycobacterial drugs. Lomefloxacin,
because of its pharamacokinetic property (long
serum elimination half-life) should merit further
evaluation as a potential supplementary drug for
the intermittent treatment of tuberculosis.
Spar f l oxac in  
Sparfloxacin is a new difluorinated quinolone
with i  vitro activityand in vivo efficacy equal to
or better than Ofloxacin and Ciprofloxacin. In a   
study carried out by Rastogi and Goh, comparison
of bactericidal action with reported serum peak
concentration has shown that Sparfloxacin has a
potential for use against the tubercle bacillus and
on 10 strains of M. tuberculosis, the MICs by
7H12 broth testing ranged from 0.5 to 1.0, 0.25 to
0.5, and 0.1 to 0.2 mg/l for Ofloxacin,
Ciprofloxacin and Sparfloxacin, respectively,
whereas MICs in solid medium ranged from 0.5 to   
1.0, 0.5 to 1.0, and 0.2 to 0.5 mg/l, respectively.33
Combination of beta lactam agents and beta
lactamase inhibitors
Mycobacteria produce beta lactamase and are
resistant to beta lactam antibiotics. Beta lactamase
stabl  penicillin like Dicloxacillin do not have
sufficient intrinsic activity against M.
tuberculosis. Recently, a group of beta lactam
drugs have been produced which, although devoid
of antibacterial activity, are potent inhibitors of
beta lactamase. The addition of one such inhibitor,
Clavulanic Acid, increased the antimycobacterial
ctivity of Amoxycillin/Ampicillin.2 The best
combination was found to be Ampicillin and
Clavulanic Acid in 1 : 1 ratio which gave a MIC
90 value of 11 mg/l. In vitro studies have also
shown that augmentin (Amoxycillin and
Clavulanic Acid) inhibits and kills most strains of
M. tuberculosis at a concentration of 4-8 mg/l of
Amoxycillin and 2-4 mg/l of Clavulanic Acid.
Another good combination was Ticarcillin and
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Clavulanic acid, which inhibited all strains of
M. tuberculosis at <32 mg/l, a clinically
achievable serum concentrations34. Ampicillin/
sulbactuam combination has been found to have
MIC values of 8/8 mg/l in 13 M. tuberculosis
s t r a i n s3 5.
Tuberactinomycin (Tuberactin, Enviomycin)
Tuberactioomycin is elaborated by strain
Streptomyces griseoverticillatus v r tuberacticus
This water soluble drug resembles structurally
Viomycin. The mechanism of action is surmised
to be similar to that of Viomycin, i.e. inhibition of
protein synthesis36.
In a study carried out at TRC, cross-resistance
was not observed between Tuberactin and
Streptomycin, H, Emb, R and Ethionamide.37
However, 15 (54%) of 28 Kanamycin-resistant
strains were not susceptible to Tuberactinomycin
at 25 mg/l.
Clinical studies with Tuberactinomycin
containing regimens have been conducted in
Japan38. The rate of sputum conversion by culture
after 6 months ranged from 73% to 80% in the
Tuberactin regimens compared to 63% in a
similar Viomycin containing regimen. In
advanced cases, this ranged from 67% to 76% in
the Tuberactin regimens compared to 59% in the
Viomycin regimen. Thus Tuberactin was better
than Viomycin and daily administered regimen
was better than biweekly administered regimen.
Amikacin and Capreomycin
The aminoglycoside antibiotic Amikacin is a
semisynthetic derivative of Kanamycin A. It has
been reported to inhibit M. uberculosis at a
concentration lower than that for Kanamycin or
Streptomycin and to be more active than either of
them in experimental murine tuberculosis and also
to be active in experimental tuberculosis in the
guinea pig.
In a study carried out by Hoffner and
Kallenius,39 out of a total of 585 M. tuberculosis
strains isolated during a 3-year period in Sweden,
resistance to S was seen in 27 (4.6%) isolates. All
but one of the S resistant isolates were susceptible
to Amikacin and none of the 263 S susceptible
isolates tested was resistant to Amikacin. From
these results, Amikacin appeared to be an
alternative to S in the treatment of patients with S
resistant M. tuberculosis.
Earlier, Allen et al40 had reported the results of
treating 4 patients with Amikacin, each of whom
had a long history of previous chemotherapy and
had multiple-resistant organisms. The activity of
Amikacin was very low, although emergence of
resistance indicated that it had some activity.
Amikacin was no more active than Kanamycin.
Since Amikacin is considerably more expensive
than Kanamycin and there appeared to be
complete cross resistant between the 2 antibiotics,
they bad concluded that there was probably no
place for its use in the chemotherapy of
tuberculosis.
Capreomycin is a polypeptide antibiotic
produced by Streptomyces spp and has the same
pharmacokinetics and toxicities as the other
aminoglycosides. It is no more effective than
Streptomycin and has an incomplete cross-
resistance with Amikacin and Kanamycin.41
Clarithromycin
Clarithromycin, anewer erythromycin
derivative, has been shown to be highly active
against multiple drug resistant MAC organisms,
besides having promising activity against various 
other potentially pathogenic NTM including M.
paratuberculosis.42 It has been shown to cause a
reduction in the bacillary load and clinical
improvement of M. avium disease in AIDS
patients.41
Conclusions
From the available information it is clear that
among the newer drags which have
antituberculosis activity and are promising,
Rifapentine shows extensive cross reaction with
Rif mpicin, and Rifabutin shows lower MIC
values in only about 10-30% M. tuberculosis
strains resistant to Rifampicin. Only the
fluoroquinolones do not cross resistance
with Rifampicin. The other drugs like Amikacin,
Capreomycin and beta lactam antibiotics may not
have any additional benefits or have not yet been
evaluated fully.
In India, under the National Tuberculosis
Programmme, SCC is being implemented at present
in about 250 districts. As a result, Rifampicin is
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being used freely in these districts in the primary
chemotherapy of sputum positive pulmonary
tuberculosis patients under programme conditions.
A large number of patients who do not seek
treatment in government institutions get treated by
private practitioners and also by other agencies,
often with Rifampicin in addition to other drugs.
A similar situation prevails in most of the other
developing countries also. In these places, the
prognosis for patients harbouring sensitive M.
tuberculosis strains and also those who harbour M.
tuberculosis strains with initial drug resistance to
S/H will be good if the patients are regular and
complete the full course of treatment. However,
under programme conditions only about 50% of
patients under SCC and about half of them under
standard chemotherapy complete the full course of
treatment. In respect of patients harbouring strains
with initial resistance to Rifampicin, the prognosis
is even more bleak. The problem gets more
complicated if these patients are also infected with
HIV.
The treatment oftuberculosis in
immunosuppressed patients isnot well
established. A regimen of Rifampicin, Isoniazid
and Ethambutol for 6 months, supplemented with
Pyrazinamide during the first 2 months has been
reported to be quite effective and able to bring
about sputum conversion in more than 80% after 3
months,43 although relapse has been reported44 and
adverse reactions to antituberculosis drugs are
frequent.45 It has been reported that corticosteroids
added to the antituberculosis chemotherapy give
dramatic clinical improvement.46 It is also known
that patients can tolerate concurrent therapy with
Azidothymidine and antimycobacterial drugs
without unacceptable toxicity.47 Currently, the
American Thoracic Society and CDC48
recommend that antituberculosis chemotherapy
should be started whenever acid-fast bacilli are
found in a specimen from a patient with AIDS or
suspected HIV infection. The treatment should be
with H, R and Z, and should be continued for a
minimum of 9 months and for at least 6 months
after culture conversion: For any person,
regardless of age, who has a positive tuberculin
test reaction and is HIV seropositive, preventive
therapy with H isrecommended. Studies have to
be undertaken to see if HIV infected individuals
treated for tuberculosis in whom subsequent
immunosuppression may lead to relapse, would
benefit from continued administration of one or
more antituberculosis drugs.49 The ideal duration
of treatmentremains to be determined because in
a recent study with a longer duration of follow-up,
6% of the patients who completed the 1 year
treatment had relapse.50 In this study, relapse was
frequent in cases of poor adherence with
premature discontinuation of treatment In India,
 the guidelines for treating tuberculosis in HIV
positive persons and chemoprophylaxis using
Isoniazid alone or in combination with other drugs
have to be worked out.
In essence, the time has come for rational
thinking and judicious use of the available
alternative drugs in the treatment of failure
pati nts. It is even more important to
acknowledge the fact that at present there is no
better substitute. than regular treatment with
the currently available antituberculosis drugs
and regimens.
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